A Clinical Study of An Antimicrobial Gauze Dressing

A Prospective Randomized Double-Blind Trial of a Polyhexamethylene Biguanide (PHMB) Impregnated Gauze Dressing for the Prevention of Chronic Wound Colonization With Resistant and Prevalent Microorganisms

The purpose of this study is to determine if a new antimicrobial gauze dressing is better than the current method of dressing open wounds with plain sterile gauze. It is hoped that the antimicrobial gauze will reduce the number of germs in the open wound and even improve the rate of healing.

Study Overview

• Status: Terminated
• Conditions: Wounds
• Intervention / Treatment: Device: KERLIX A.M.D. Gauze

Detailed Description

Without adequate debridement, chronically infected wounds persist and form a nidus for the acquisition of antimicrobial-resistant microorganisms. Multiple studies state that patients with chronic wounds were colonized with one or more resistant bacteria, and that the presence of a chronic wound or decubitus ulcer was associated with a statistically increased likelihood of colonization with methicillin-resistant Staphylococcus aureus (MRSA), ciprofloxacin-resistant gram-negative bacilli (GNB),colonization and infection with ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae.

Recently, a newly formulated gauze dressing impregnated with an antiseptic agent has become available. This product offers the promise of a combined benefit of wet-to-dry mechanical debridement, while providing high local concentrations of a potent antiseptic to prevent colonization and infection of the wound by resistant microorganisms, potentially enhancing wound healing.

This study proposes to determine if use of the antimicrobial gauze in routine wound care results in a lower rate of chronic wound colonization with resistant microorganisms and prevalent microorganisms as compared to standard wound care (with non-antimicrobial gauze).

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5S 1B2
      • Sunnybrook & Women's College Health Sciences Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The subject is receiving care at the study wound care clinics.
2. The subject is 18 years of age or older.
3. The subject or authorized representative has signed the Informed Consent form.
4. The subject has a chronic wound as a result of pressure ulceration (grade III and IV ulcers only), underlying vascular disease ("leg ulcer"), diabetes mellitus (grade 2 and 3 ulcers only), or recent surgery.

Exclusion Criteria:

1. The subject has a chronic ulcer that is a result of a condition other than that defined in the inclusion criteria.
2. The subject has stage I and II pressure ulceration.
3. The subject has a superficial (grade 0 or 1) or limb-threatening diabetic foot ulceration (grade 4 or 5).
4. The subject has a leg ulcer related to carcinoma.
5. The subject is scheduled to go for amputation or surgical flap procedure as a result of an open wound.
6. Subject is scheduled to receive a V.A.C.® (Vacuum Assisted Closure) Dressing [V.A.C.® (Vacuum Assisted Closure) Dressing KCI, Kinetic Concepts, Inc., San Antonio, TX].
7. The subject has extensive burns or another acute diffuse skin condition (Stevens-Johnson Syndrome).
8. The subject has a history of hypersensitivity to Chlorhexidine Gluconate (CHG) or Polyhexamethylene Biguanide (PHMB).
9. The subject has severe systemic infection characterized by the systemic inflammatory response syndrome.
10. The subject has taken part in a wound healing study within the past month.
11. The subject has suspected or confirmed underlying osteomyelitis contiguous to the ulcer and is not receiving systemic antimicrobial therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Rate of chronic wound colonization with resistant/prevalent microorganisms.

Secondary Outcome Measures

Outcome Measure
Rate of wound surface area healing over time; Antibiotic utilization.

Collaborators and Investigators

• Sponsor: Tyco Healthcare Group
• Investigators: Study Director: Tonya M. Eggleston, RN, MPH, Tyco Healthcare/Kendall

Study record dates

Study Major Dates

• Study Start: June 1, 2005
• Study Completion: August 1, 2007

Study Registration Dates

• First Submitted: September 12, 2005
• First Submitted That Met QC Criteria: September 12, 2005
• First Posted (Estimate): September 20, 2005

Study Record Updates

• Last Update Posted (Estimate): November 19, 2007
• Last Update Submitted That Met QC Criteria: November 16, 2007
• Last Verified: November 1, 2007

More Information

Terms related to this study

• Other Study ID Numbers: Study Protocol 331.18